Leap Therapeutics Inc (NAS:LPTX)
$ 2.495 -0.015 (-0.6%) Market Cap: 95.47 Mil Enterprise Value: 41.71 Mil PE Ratio: 0 PB Ratio: 1.35 GF Score: 44/100

Leap Therapeutics Inc ESMO 2021 DisTinGuish Study Conference Call Transcript

Sep 17, 2021 / 12:00PM GMT
Release Date Price: $26.5 (+4.74%)
Operator

Good day, everyone, and welcome to the Leap Therapeutics DKN-01 Clinical Investigator Conference Call. (Operator Instructions) Please be advised that today's call is being recorded at the company's request. At this time, I'd now I'd like to turn the call over to Dr. Cynthia Sirard, Chief Medical Officer of Leap. Please begin.

Cynthia A. Sirard
Leap Therapeutics, Inc. - Chief Medical Officer

Thank you, operator. Welcome, and thank you to those of you joining us today for an update on Leap Therapeutics DKN-01 development program. I'm Cynthia Sirard, and with me today are Dr. Jaffer Ajani, Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at the University of Texas, MD Anderson Cancer Center in Houston, Texas.

In addition, we have Dr. Samuel Klempner, who's a member of the faculty at Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts. As well, we have Douglas Onsi, the President and Chief Executive Officer at Leap.

This call is being accompanied by a slide deck. So I will ask

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot